Core Scientific Q1 EPS Forecast Decreased by Roth Capital

Core Scientific, Inc. (NASDAQ:CORZ) – Roth Capital lowered their Q1 2025 earnings per share estimates for Core Scientific in a research report issued on Wednesday, April 9th. Roth Capital analyst D. Aftahi now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their previous estimate of ($0.11). The consensus estimate for Core Scientific’s current full-year earnings is $0.52 per share. Roth Capital also issued estimates for Core Scientific’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.43) EPS and Q1 2026 earnings at ($0.02) EPS.

Core Scientific (NASDAQ:CORZ) last released its earnings results on Wednesday, February 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.09. The firm had revenue of $94.93 million during the quarter, compared to analysts’ expectations of $97.07 million.

CORZ has been the topic of a number of other research reports. Cantor Fitzgerald lowered their target price on shares of Core Scientific from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Craig Hallum assumed coverage on Core Scientific in a research report on Tuesday, January 21st. They issued a “buy” rating and a $24.00 price objective on the stock. Keefe, Bruyette & Woods started coverage on Core Scientific in a research report on Monday, January 27th. They set an “outperform” rating and a $22.00 target price for the company. Compass Point lowered their price target on Core Scientific from $26.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, Needham & Company LLC dropped their price target on Core Scientific from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Fifteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.07.

Core Scientific Price Performance

CORZ opened at $6.85 on Monday. The firm has a market cap of $2.02 billion, a P/E ratio of -1.27 and a beta of 6.80. Core Scientific has a 1-year low of $2.61 and a 1-year high of $18.63. The company has a 50 day simple moving average of $9.16 and a two-hundred day simple moving average of $12.65.

Insider Buying and Selling

In related news, CEO Adam Taylor Sullivan sold 369,712 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $16.24, for a total value of $6,004,122.88. Following the completion of the transaction, the chief executive officer now owns 3,758,793 shares of the company’s stock, valued at approximately $61,042,798.32. This trade represents a 8.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Todd A. Becker sold 134,250 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $10.75, for a total value of $1,443,187.50. Following the sale, the director now directly owns 195,687 shares in the company, valued at $2,103,635.25. The trade was a 40.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 530,041 shares of company stock worth $7,870,352. Insiders own 32.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CORZ. Wealth Enhancement Advisory Services LLC grew its holdings in Core Scientific by 25.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 98,077 shares of the company’s stock valued at $1,378,000 after purchasing an additional 20,000 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Core Scientific by 48.0% during the third quarter. JPMorgan Chase & Co. now owns 437,812 shares of the company’s stock valued at $5,192,000 after buying an additional 142,068 shares during the last quarter. FNY Investment Advisers LLC grew its stake in shares of Core Scientific by 35.8% during the fourth quarter. FNY Investment Advisers LLC now owns 190,747 shares of the company’s stock valued at $2,679,000 after buying an additional 50,275 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Core Scientific in the fourth quarter worth approximately $527,000. Finally, FMR LLC bought a new stake in shares of Core Scientific during the 3rd quarter worth approximately $2,903,000.

About Core Scientific

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.